Related Experiment Video

Updated: Aug 29, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

The potential role of antileukotriene drugs in atherosclerosis

Rainer Spanbroek1, Andreas J R Habenicht

  • 1Institute of Vascular Medicine, Friedrich-Schiller University of Jena Medical School, Erfurt, Germany. spanbroek@zmkh.ef.uni-jena.de

Drug News & Perspectives
|December 12, 2003
PubMed

Insights

Developing drugs for atherosclerosis is challenging. New research highlights the role of leukotrienes (LTs) in inflammation and immune responses in advanced atherosclerosis, suggesting potential anti-LT drug development.

Area of Science:

  • Cardiovascular Science
  • Immunology
  • Pharmacology

Background:

  • Atherosclerosis drug development presents significant challenges.
  • Advanced human atherosclerotic lesions reveal new insights into inflammation and immune responses.
  • Leukotrienes (LTs) are potent inflammatory mediators implicated in disease processes.

Purpose of the Study:

  • To explore the role of leukotrienes (LTs) in the development of atherosclerosis (atherogenesis).
  • To consider the potential of developing anti-leukotriene (anti-LT) drugs for treating atherosclerosis.

Main Methods:

  • Analysis of recent studies on advanced human atherosclerotic lesions.
  • Investigation of the 5-lipoxygenase pathway expression in diseased arteries.
  • Consideration of pharmacological strategies for anti-LT drug development.

Main Results:

  • The 5-lipoxygenase pathway is expressed in diseased arteries.
  • Leukotrienes (LTs) are powerful inflammatory mediators.
  • Advanced atherosclerotic lesions provide new information on inflammatory and immune mechanisms.

Conclusions:

  • Leukotriene roles in atherogenesis warrant further investigation.
  • Pharmacological targeting of leukotrienes (LTs) presents a potential therapeutic strategy for atherosclerosis.
  • Developing anti-LT drugs could offer a novel approach to treating advanced atherosclerosis.

More Related Videos

Flow Cytometry Analysis of Immune Cells Within Murine Aortas15:15

Flow Cytometry Analysis of Immune Cells Within Murine Aortas

Published on: July 1, 2011

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...